Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Drugs Don't Work for Many Indian AIDS Patients

August 11, 2006

India's National AIDS Control Organization has decided its five-year HIV strategy will include increasing access to free first-line HIV drugs, according to Dr. Po-Lin Chan, a World Health Organization advisor to the program. However, NACO has decided it cannot afford to introduce newer second-line drugs for distribution to AIDS patients whose virus is resistant to first-line therapies.

India introduced free antiretroviral drug (ARV) treatment in 2004. About 500,000 patients need ARVs, but just 35,000 patients (7 percent) receive free treatment through NACO. By 2012, NACO aims to have 300,000 patients on ARVs.

For the most adherent patients, NACO expects ARV treatment failure of 2-3 percent per year, or 1,000 patients at current treatment rates. However, critics say poor local medical advice and clinic supply interruptions mean that many more patients will develop resistance - problems NACO is working to address.

Advertisement
"We have to ask ourselves what the priorities are," said Chan. "Probably 90 percent of patients will need first-line drugs for quite some time, so let's keep them on them as long as possible."

Second-line ARVs cost 4,000-8,500 rupees ($85-180 US) for a month's supply, compared with 450 rupees ($10 US) for first-line drugs.

"I think prices can be considerably lower than they are today," said Indrani Gupta, head the New Delhi Institute of Economic Growth's unit for health policy research. "But there isn't yet a critical mass of demand for second-line drugs so there's no incentive for manufacturers to bring down prices."

Brazil is the only resource-poor country that offers free second-line drugs to its citizens, said Chan. It also spends much more on treatment, though its HIV caseload is only about one-tenth of India's. India spends much more on HIV prevention than treatment, though its generic drug manufacturing sector provides most of the world's cheap ARVs.

Back to other news for August 11, 2006

Adapted from:
Reuters
08.10.06; Jonathan Allen


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement